CA2656698C - Cannabinoids for use in the treatment of neuropathic pain - Google Patents

Cannabinoids for use in the treatment of neuropathic pain Download PDF

Info

Publication number
CA2656698C
CA2656698C CA2656698A CA2656698A CA2656698C CA 2656698 C CA2656698 C CA 2656698C CA 2656698 A CA2656698 A CA 2656698A CA 2656698 A CA2656698 A CA 2656698A CA 2656698 C CA2656698 C CA 2656698C
Authority
CA
Canada
Prior art keywords
thc
cbd
cbme
pain
neuropathic pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2656698A
Other languages
English (en)
French (fr)
Other versions
CA2656698A1 (en
Inventor
Geoffrey Guy
Barbara Costa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of CA2656698A1 publication Critical patent/CA2656698A1/en
Application granted granted Critical
Publication of CA2656698C publication Critical patent/CA2656698C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2656698A 2006-06-23 2007-06-21 Cannabinoids for use in the treatment of neuropathic pain Active CA2656698C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0612512A GB2439393B (en) 2006-06-23 2006-06-23 Cannabinoids for use in the treatment of neuropathic pain
GB0612512.4 2006-06-23
PCT/GB2007/002315 WO2007148094A1 (en) 2006-06-23 2007-06-21 Cannabinoids for use in the treatment of neuropathic pain

Publications (2)

Publication Number Publication Date
CA2656698A1 CA2656698A1 (en) 2007-12-27
CA2656698C true CA2656698C (en) 2015-10-13

Family

ID=36803806

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2656698A Active CA2656698C (en) 2006-06-23 2007-06-21 Cannabinoids for use in the treatment of neuropathic pain

Country Status (8)

Country Link
US (3) US20100016418A1 (https=)
EP (1) EP2037902B1 (https=)
JP (2) JP5399898B2 (https=)
CA (1) CA2656698C (https=)
ES (1) ES2429406T3 (https=)
GB (1) GB2439393B (https=)
PL (1) PL2037902T3 (https=)
WO (1) WO2007148094A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8449908B2 (en) 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2471523A (en) * 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2524689B (en) * 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US20150313868A1 (en) 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
GB2524469A (en) 2014-02-14 2015-09-30 Kind Consumer Ltd A cannabinoid inhaler and composition therefor
US9918961B2 (en) 2014-02-19 2018-03-20 Kind Consumer Limited Cannabinoid inhaler and composition therefor
EP3134393B1 (en) * 2014-04-21 2020-12-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Cyclohexenyl compounds, compositions comprising them and uses thereof
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9844518B2 (en) 2014-09-30 2017-12-19 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
US20160298151A1 (en) 2015-04-09 2016-10-13 Sher Ali Butt Novel Method for the cheap, efficient, and effective production of pharmaceutical and therapeutic api's intermediates, and final products
EP3302033A4 (en) 2015-05-28 2018-10-31 Tweed Inc. Cannabis plants having modified expression of thca synthase
CA3006182A1 (en) * 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
AU2017260706B2 (en) 2016-05-04 2023-05-11 Inmed Pharmaceuticals Inc. Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
WO2018000094A1 (en) 2016-06-29 2018-01-04 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
BR112020004058A2 (pt) * 2017-09-01 2020-09-01 Pureform Global, Inc. composições de canabidiol sintétco e métodos de fazer as mesmas
SG11202002169TA (en) * 2017-09-15 2020-04-29 Zelda Therapeutics Operations Pty Ltd Composition and method for treating autism
EP3684353A4 (en) * 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USES FOR PAIN TREATMENT
US20190183849A1 (en) * 2017-10-21 2019-06-20 Alexander Kariman Compound and method for treatment of diseases and disorders
AU2017443426A1 (en) * 2017-12-20 2020-07-02 Hanyi Bio-Technology Company Ltd. Use of cannabidiol or cannabis extract in preparation of skin whitening products
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
SI25373A (sl) * 2018-05-08 2018-08-31 Danijela Marković Naravna orodisperzibilna tableta
EP3806845A4 (en) * 2018-06-15 2022-04-06 Cannpal Animal Therapeutics Limited CANNABINOID COMPOSITION AND METHODS OF TREATMENT WITH IT
AU2019335372B2 (en) * 2018-09-05 2024-12-12 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020220092A1 (en) * 2019-05-01 2020-11-05 Cannadol Pharmaceuticals Compositions and methods for pain and anxiety relief
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
MX2022005571A (es) * 2019-11-07 2022-06-09 Amyris Inc Composiciones y metodos para administrar cannabinoides a la piel.
US20210401794A1 (en) * 2020-06-30 2021-12-30 Np Pharma Holdings, Llc Methods of Using Cannabinoid Compositions for Inducing and Promoting Sleep
CA3091622A1 (en) 2020-08-28 2022-02-28 Teresa Ann Hanlon Pain relieving formulations containing cannabis and methods of making same
WO2022159507A1 (en) * 2021-01-19 2022-07-28 Merit Therapeutics, Inc. Combination of cannabinoids with additional therapeutic agents for treating diseases or disorders
WO2026033228A1 (en) * 2024-08-08 2026-02-12 Curaleaf International Limited Formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB2391865B (en) * 2002-08-14 2005-06-01 Gw Pharma Ltd Improvements in the extraction of pharmaceutically active components from plant materials
SI1542657T1 (sl) * 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
GB2394894B (en) * 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain

Also Published As

Publication number Publication date
US20120245224A1 (en) 2012-09-27
JP5399898B2 (ja) 2014-01-29
CA2656698A1 (en) 2007-12-27
EP2037902B1 (en) 2013-07-03
PL2037902T3 (pl) 2013-12-31
JP2009541479A (ja) 2009-11-26
ES2429406T3 (es) 2013-11-14
EP2037902A1 (en) 2009-03-25
US20190224140A1 (en) 2019-07-25
GB0612512D0 (en) 2006-08-02
US20100016418A1 (en) 2010-01-21
GB2439393A (en) 2007-12-27
GB2439393B (en) 2011-05-11
JP2013241471A (ja) 2013-12-05
WO2007148094A1 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
CA2656698C (en) Cannabinoids for use in the treatment of neuropathic pain
JP6147249B2 (ja) 神経因性疼痛の治療において使用するためのカンナビノイド
US10660872B2 (en) Methods for treatment of cognitive decline
US20100035978A1 (en) Combination of cannabinoids for the treatment of peripheral neuropathic pain
KR20070039499A (ko) 관절염 질환 및/또는 증상 치료용 약학적 조성물
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
US11395813B1 (en) Cannabinoids based pharmaceutical composition
US12357587B2 (en) Cannabinoid monoterpene based pharmaceutical topical composition for musculoskeletal pain
NZ618246B2 (en) Cannabinoids for use in the treatment of neuropathic pain

Legal Events

Date Code Title Description
EEER Examination request
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251029

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260209

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260210